Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Lenvatinib||Phase I||Actionable||In a Phase I trial, Lenvima (lenvatinib) demonstrated safety and preliminary anti-tumor activity in patients with advanced solid tumors (PMID: 22516948).||22516948|
|Unknown unknown||Advanced Solid Tumor||not applicable||Lenvatinib||Phase I||Actionable||In a Phase I trial, Lenvima (lenvatinib) treatment resulted in partial response in 11.7% (9/77) and stable disease in 51.9% (40/77) of patients with advanced solid tumors (PMID: 26169970).||26169970|
|PubMed Id||Reference Title||Details|
|(22516948)||A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.||Full reference...|
|(26169970)||Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.||Full reference...|